IKCS: North America
November 4-5, 2022

Hyatt Regency Austin
Austin, Texas, USA

Registration, Hotel, and Abstract Submission are Now Open!

Important Dates

Review the important dates below for 2022 IKCS: North America

Abstract Submissions Open Now Open- May 2022
Program At a Glance AvailableNow Available- May 2022
Registration Opens Now Open- May 2022
Hotel Booking Opens Now Open- May 2022
Program Details and Speakers ReleasedNow Available- June 2022
Abstract Submission Deadline
(all complete Regular, TPS, and Case Report submissions, and all LBA Placeholders due at this time)
August 2, 2022 at 11:59 PM PDT
LBA Submission Deadline (LBA Placeholder required by August 2 deadline)August 31, 2022 at 12:00 PM (Noon) PDT (placeholder required by August 2, 2022)
Abstract Notifications Sent to Lead AuthorsEarly September 2022
Early Registration Deadline September 21, 2022 at 11:59 PM PDT
Abstract Withdrawal Deadline
(Withdrawal requests must be submitted by the Lead Author to [email protected])
September 30, 2022
Abstract Titles ReleasedEarly October 2022
Deadline to cancel Hotel Reservations without feesTBD
Presentation Slides DueSeptember 19, 2022
Poster Uploads DueOctober 21, 2022
Abstracts Released and Hybrid Meeting Platform AvailableNovember 1, 2022 at 5:00 PM ET
Meeting DatesNovember 4-5, 2022

Registration, Hotel, and Travel Information

Registration

Review Registration Rates and Categories below.

CategoryEarly Registration Rate (Register by September 21, 2022 at 11:59 PM PDT)Regular Registration Rate (After September 21, 2022)
In-person Physician/Scientist$375$500
Virtual Only Physician/Scientist$300$400
Group In-person Physician/Scientist (this rate includes 1 in-person Physician/Scientist registration and 5 virtual Physician/Scientist registrations)$550$700
In-person Allied Health Professional$260$350
Virtual Only Allied Health Professional$210$280
In-person Physician In-Training$260$350
Virtual Only Physician In-Training$210$280
In-person Patient/Advocate/CaregiverComplimentary* $50
Virtual Only Patient/Advocate/CaregiverComplimentary*Complimentary*
In-person Industry$480$650
Virtual Only Industry$390$520
In-person MediaComplimentary**Complimentary**
Virtual Only MediaComplimentary**Complimentary**
*If you are a Patient, Advocate, or Caregiver please contact [email protected] with your interest in attending IKCS. This Registration category is reserved for Patients, Advocates, and Caregivers who do not meet one of the other registration categories.

**If you are a Media employee interested in attending IKCS, please contact [email protected] with your interest and plan for meeting coverage. This Registration category is reserved only for Media.

SPECIAL REGISTRATION OPPORTUNITY FOR PHYSICIANS IN TEXAS AND LOUISIANA
Kidney Cancer Association to collect information about kidney cancer disparities

Physicians in Texas and Louisiana may be eligible for complimentary IKCS: North America Registration by completing the KCA Disparities survey. Email [email protected] to request the survey link. The first 25 survey respondents from Texas and Louisiana will be eligible for complimentary IKCS: North America Registration.

Hotel Accommodations

Meeting Venue: The Hyatt Regency Austin Texas
Venue Address: 208 Barton Springs Rd, Austin, TX 78704

Health and Safety

Review Health and Safety Information for the 2022 IKCS: North America meeting.

Program

View the Preliminary Program at a Glance! Speakers and additional Program Information will become available in July 2022.

Abstracts

Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to 2022 IKCS: North America.

  • All submitters are required to create a free account with Cadmium to access the abstract submitter.
  • Important Deadlines:
    • Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): AUGUST 2, 2022 AT 11:59 PM PDT
    • LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): August 31, 2022 at 12:00 PM (Noon) PDT
      • Additional instructions will be sent to lead authors to complete their LBA submissions.
    • Abstract Notifications will be sent to lead authors in September 2022.
    • LBA lead authors will receive abstract notifications in September 2022.
  • Abstract Submission Types:
    • Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)
    • Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)
    • Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)
    • Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)
  • Abstract Sections:
    • Abstract Title: The title should objectively describe the study and should not include proprietary drug names.
    • Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. All abstracts should be structured into four sections:
      • Background
      • Methods
      • Results
      • Conclusions
    • Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted.
    • Authors: The maximum number of authors permitted is 20.
      • Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has financial relationships with ACCME-defined ineligible companies, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].
    • Conflict of Interest Disclosure: Presenting authors must submit a Conflict of Interest disclosure identifying financial relationships with ACCME-defined ineligible companies. Co-authors do not need to submit a COI Disclosure.
  • Abstract Policies
    • Confidentiality Policy: Abstracts are confidential at the time of submission. KCA will release full abstracts on November 1, 2022 leading up to the meeting.
    • Abstract Supplement: Abstracts presented at IKCS: North America are published in a supplement of the Kidney Cancer Journal, the official journal of the KCA.
    • KCJ Open Access Policy
    • Permissions Policy
    • Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author and will not be published/printed by KCA/KCJ.
Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

  • Basic Science
  • Disparities in Cancer, Care, and Access
  • Diagnostics
  • Financial Toxicity- Care Delivery/Health Outcomes
  • Imaging
  • Patient-reported Outcomes
  • Post-treatment Surveillance
  • Prevention and Screening
  • Quality of Care and Quality Improvement
  • Real-World Evidence
  • Survivorship
  • Treatment Toxicities and Symptom Management
  • Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)
  • Therapeutics (Local- Primary and Metastatis)
  • Tumor Biology, Biomarkers, and Pathology
  • Other
Late-breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBA Abstracts should be studies where results and conclusions are not yet available by the August 2 deadline, but will be available by the August 31, 2022 12:00 PM (Noon) PDT deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the August 2, 2022 11:59 PM PDT abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by the August 31, 2022 LBA deadline.

Trials in Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TPS abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: North America Scientific Planning Committee. Abstract notifications will be sent to lead authors in September 2022.

Abstract-Associated Awards- New for 2022

IKCS: North America Merit Awards

Merit Awards are given to early-career abstract authors of high-quality submitted abstracts. To apply for a Merit Award, the presenting author should select “Yes” to the question “would you like to apply for a merit award?” The presenting author is required to upload a CV/Resume and a Letter of Support from their training program supervisor substantiating the applicant’s good standing in their training program.

Merit Award Eligibility Requirements:
– Must have a doctorate-level advanced degree (MD, PhD, PharmD, etc.) completed at the time of submission
– Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position
– Must upload a CV/Resume and Letter of Support showing participation and good standing in training program

The IKCS Scientific Planning Committee will select recipients to receive a merit award for the best original submissions.
*Please note: Trials in Progress presentations will not be eligible to receive a merit award.

  • First place: $500 USD and complimentary meeting registration
  • Second place: $250 USD and complimentary meeting registration
  • Third place: $100 USD and complimentary meeting registration
Abstract Presenter Guidelines

All accepted abstracts and lead authors are requested to present in-person at 2022 IKCS: North America in Austin, Texas. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online.

All Abstract Presenters must register for the conference.

All accepted abstracts will be published in the Kidney Cancer Journal, the official journal of the Kidney Cancer Association. KCJ Open Access Policy

Oral Abstract Presenter Guidelines

  • Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT presentation
  • Slide Upload Deadline: PPT slides are due in the presenter portal by September 19, 2022. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Download the PPT slide template
  • Conflict of Interest Disclosure: Oral Abstract Presentations must include in a COI Disclosure slide
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by September 30, 2022. Requests received after this date cannot be guaranteed removal from the program.
  • Corresponding Poster: Oral Abstract presenters should also prepare a poster presentation to accompany their oral presentation.

Poster Presenter Guidelines

  • Poster Presenters should prepare a PDF and printed poster. Attendees will have the opportunity to visit posters in-person onsite and view electronic versions online.
  • ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal by October 21, 2022. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Printed Posters: Poster Presenters should bring a printed poster onsite to hang on an assigned poster board for the duration of the meeting.
  • Size: Printed posters should not exceed 42 inches by 42 inches (106 cm by 106 cm). There will be 2 posters per board side. Poster hanging materials will be provided onsite.
  • Printing: Poster Presenters should arrange their own poster printing and carry their poster onsite. If a Poster Presenter is unable to attend in-person, they should arrange for a colleague to carry the poster onsite or contact KCA at [email protected] to obtain shipping information to send the poster to the meeting.
  • KCA is not responsible for costs associated with printing and shipping posters.
  • Template: No specific Poster Template is required.
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by September 30, 2022. Requests received after this date cannot be guaranteed removal from the program.
Abstract Release Information

Abstract texts will be released on the hybrid meeting platform on November 1, 2022 at 5:00 PM ET.

Poster Presentations will become available beginning November 4, 2022. PDF versions of presentation slides will become available during the specific session for the presentation.

Additionally, all accepted abstracts will be published in the Kidney Cancer Journal, the official journal of the Kidney Cancer Association. KCJ Open Access Policy. The Kidney Cancer Journal also publishes an IKCS special issue supplement which will come out in December 2022.

Continuing Medical Education (CME) Information

Continuing Medical Education (CME) Information

Jointly provided by The France Foundation and the Kidney Cancer Association.


Target Audience: This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

Statement of Need: Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, researchers, and care team members to help promote learning and collaboration for advancement in the renal cancer space.

Educational Learning Activity Objectives: Upon completion of this course, the participants should be able to:

  • Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
  • Identify the novel approaches to non-clear RCC patient management
  • Understand the role of the tumor microenvironment in kidney cancer
  • Discuss how to design biomarker driven clinical trials in kidney cancer

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by ACCME to provide continuing medical education for physicians.

Credit Designation:

Physicians: Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy: In accordance with ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the Kidney Cancer Association who control content have no relevant financial relationships to disclose.

2022 IKCS: North America Planning Committee Disclosures are available here.

IKCS: North America Scientific Planning Committee

Thank you to our 2022 IKCS: North America Planners!

Eric A. Singer, MD, MA, FACS
Rutgers Cancer Institute of New Jersey
Planning Committee Co-Chair
Tian Zhang, MD
UT Southwestern Medical Center
Planning Committee Co-Chair
Maria Carlo, MD
Memorial Sloan Kettering Cancer Center
Kiran Virdee, RN, BSN, CCRN
Memorial Sloan Kettering Cancer Center
Jodi Maranchie, MD
University of Pittsburgh
Vitaly Margulis, MD
UT Southwestern Medical Center
Bradley McGregor, MD
Dana-Farber Cancer Institute
Phillip Pierorazio, MD
Penn Presbyterian Medical Center
Laura Wood, RN, MSN, OCN, Retired
Cleveland Clinic Cancer Institute
Yousef Zakharia, MD, University of Iowa Carver College of Medicine

View 2022 IKCS: North America Planning Committee Disclosures.

Sponsorship and Exhibitor Opportunities

Please contact [email protected] for more information.

Faculty Presentation Guidelines

Speaker PPT Slide Presentations are due in the Faculty/Speaker Portal by September 19, 2022.

Meeting Format

Meeting Format: 2022 IKCS: North America will be a hybrid event offering in-person and virtual participation options for meeting attendees. Faculty are expected to attend in-person in, however, reasonable adjustments may be considered due to COVID-19 related travel restrictions. Some onsite sessions will be live-streamed to virtual attendees.

Conflict of Interest Disclosure and Session Preparation Information

Conflict of Interest Disclosure: Confirmation of any faculty invitation requires agreement to abide by Conflict of Interest procedures in addition to policies set forth by the Kidney Cancer Association, The France Foundation, and the Accreditation Council for Continuing Medical Education (ACCME) for content and presentation. All Faculty are required to submit a full disclosure of financial interests with commercial entities. All Conflict of Interest Disclosures will be reviewed by The France Foundation for final approval and participation in the program. Failure to submit a Conflict of Interest Disclosure will prohibit participation in the program.

Session Preparation: Speakers should upload their presentation slides by October 5, 2022. Slides will be reviewed by Session Chairs/Moderators and CME regulators to ensure compliance with CME guidelines, minimize content overlap between sessions, and help presentations contribute to a cohesive and educational session. Speakers may receive recommendations for slide adjustments. Speakers who are only able to participate virtually will receive instructions to pre-record their presentations prior to the meeting, along with instructions to participate in the live panel Q+A at the end of the session.

Download the 2022 IKCS: North America PPT Template

Faculty Benefits: 2022 IKCS: North America Faculty may be eligible for benefits including Registration, Hotel accommodation, and travel assistance. Faculty will receive details and instructions for meeting arrangements directly via email. If you have questions please contact [email protected]